TherapeuticsMD (TXMD) Gross Profit (2011 - 2023)
TherapeuticsMD's (TXMD) quarterly Gross Profit came in at $502000.0 in Q4 2023, down 99.27% YoY from $68.6 million in Q4 2022, and up 1047.17% on a QoQ basis from -$53000.0 in Q3 2023.
TherapeuticsMD (TXMD) Gross Profit (2011 - 2023) Analysis & Trends
TherapeuticsMD (TXMD) has 13 years of Gross Profit data on file, last reported at $502000.0 in Q4 2023.
- Quarterly Gross Profit fell 99.27% year-over-year to $502000.0 in Q4 2023, while the trailing twelve-month figure through Dec 2023 was $1.3 million (down 98.43% YoY) and the FY2023 annual result came in at $1.3 million, down 98.1% from the prior year.
- Gross Profit advanced to $502000.0 in Q4 2023, from -$53000.0 in the prior quarter.
- In the past five years, Gross Profit ranged from a high of $68.6 million in Q4 2022 to a low of -$53000.0 in Q3 2023.
- A 5-year average of $13.6 million and a median of $13.5 million in 2019 frame the typical range for Gross Profit.
- Annual changes were most pronounced in 2019 — Gross Profit surged 702.7% — and 2023, when it slumped 99.27%.
- Tracing TXMD's Gross Profit over 5 years: stood at $13.0 million in 2019, then jumped by 30.52% to $17.0 million in 2020, then declined by 17.98% to $13.9 million in 2021, then surged by 391.83% to $68.6 million in 2022, then tumbled by 99.27% to $502000.0 in 2023.
- The last three Gross Profit figures came in at $502000.0 (Q4 2023), -$53000.0 (Q3 2023), and $437000.0 (Q2 2023), per Business Quant data.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|